Calcium antagonists have become available for the treatment of hypertension and ischemic heart diseases. Large clinical trials have demonstrated that calcium antagonists prevent cardiovascular mortality and morbidity. Epidemiologic studies have shown insulin resistance is an independent predict factor for cardiovascular outcome. Cardiovascular diseases, including hypertension, diabetes mellitus, and hyperlipidemia are associated with insulin resistance. Insulin resistance is an initial step in atherosclerosis, leading to increase in the incidences of cardiovascular outcome. From a clinical perspective, it is important to select an appropriate intervention which is effective in improving insulin resistance in cardiovascular diseases. In this review, we would like to focus on the effects of calcium antagonists on insulin resistance (insulin sensitivity).